Bavarian Nordic launches chikungunya vaccine trial for paediatric population
Bavarian Nordic has commenced a Phase III trial of its chikungunya vaccine, CHIKV VLP, targeting the paediatric population aged two …
Post
-
-
Novo Nordisk ramps up obesity fight, advances amycretin to Phase III
Novo Nordisk is progressing both subcutaneous and oral versions of amycretin into Phase III trials for patients with obesity and …
-
Novartis reports positive results from Phase IIIB study of iptacopan for PNH
Novartis has reported positive outcomes from the multi-centre Phase IIIB APPULSE-PNH study of oral Fabhalta (iptacopan) in adults with paroxysmal …
-
Exploring tau and amyloid beta PET positivity and late-life mood disorders
The relationship between neurodegenerative conditions such as Alzheimer’s disease and late-life mood disorders (LLMDs), including late-life depression (LLD) and late-life …
-
AI could personalise clinical trial consent, but privacy concerns remain
Artificial intelligence (AI) is revolutionising clinical trials, offering ways to improve the consent process, but concerns regarding the complete reliability …
-
MSD begins Phase III trial of dengue vaccine
Merck & Co (MSD) has initiated the randomised MOBILIZE-1 Phase III trial to assess the immunogenicity, efficacy, and safety of …
-
Wes Streeting: £29bn NHS boost ‘substantial’ but reform still needed
A £29bn investment into the National Health System (NHS) is ‘substantial’, but reform of the system is essential to ‘fix …
-
Customs simplified: the need to streamline pharma shipments
Pharmaceutical supply chains continue to be disrupted by a range of geopolitical factors, including global conflict, economic uncertainty, and especially …
-
ImmuneWalk presents topline data from Phase I trial’s SAD part of IW-601
ImmuneWalk Therapeutics has presented positive topline data from the single ascending dose (SAD) part of the randomised, first-in-human Phase I …
-
Clinician capacity remains a major bottleneck in UK’s push for cancer trials
While encouraged by revised regulations aimed at boosting UK clinical studies, experts say busy schedules of NHS workers present a …
-
Ionis doses first subject in Phase III trial of Angelman syndrome therapy
Ionis Pharmaceuticals has dosed the first subject in the global, randomised Phase III REVEAL trial of investigational ION582, aimed at …
-
J&J’s Tremfya reduces active psoriatic arthritis symptoms in Phase IIIb trial
Johnson & Johnson (J&J) has reported that Tremfya (guselkumab) minimised the symptoms and signs of active psoriatic arthritis (PsA) at …
-
Policy changes and digital strategies guide oncology research
Against the backdrop of the recent US Food and Drug Administration’s (FDA) staff cuts and administrative realignment, understanding accelerated approval …
-
Gilead hit with FDA clinical hold for batch of HIV trials
The US Food and Drug Administration (FDA) has placed a clinical hold on several of Gilead’s trials evaluating two HIV …
-
NHS to receive £29bn funding boost
The UK’s National Health Service (NHS) is receiving a £29bn ($39.1bn) funding boost, reflecting a 3% annual rise on current …
